English
French
Press Release
|
27 |
Dec 2016 |
IntelGenx Announces Development and Commercialization Agreement with Endo Ventures... |
|
14 |
Dec 2016 |
IntelGenx and RedHill Biopharma Announce Definitive Agreement for Commercialization of RIZAPORT(R) for Migraines with Ph... |
|
01 |
Dec 2016 |
IntelGenx Strengthens Partnership with Chemo Group by Signing a Co-Development Term Sheet for an Additional Product... |
|
21 |
Nov 2016 |
IntelGenx Secures a License For Tadalafil Erectile Dysfunction Dosing Patent... |
|
10 |
Nov 2016 |
IntelGenx Reports Profitable Third Quarter with Increased Growth in Revenues from Second Quarter... |
|
01 |
Nov 2016 |
IntelGenx to Report Third Quarter 2016 Financial Results on November 10, 2016... |
|
21 |
Sep 2016 |
IntelGenx and RedHill Biopharma Announce RIZAPORT(R) Commercialization Term Sheet with Pharmatronic Co. for Korea... |
|
16 |
Sep 2016 |
IntelGenx Grants Stock Options... |
|
12 |
Sep 2016 |
IntelGenx Announces Development and Commercialization Agreement for Three Products with Chemo Group, A Global Pharmaceut... |
|
07 |
Sep 2016 |
IntelGenx to Present at the 18th Annual Rodman & Renshaw Global Investment Conference and the 11th Annual Singular Resea... |
|
22 |
Aug 2016 |
IntelGenx Reports Second Quarter 2016 Financial Results and Appointment of New Director... |
|
22 |
Aug 2016 |
IntelGenx Announces Successful Clinical Study for Montelukast for the Treatment of Degenerative Diseases of the Brain... |
|
05 |
Aug 2016 |
IntelGenx Announces Sale of Forfivo XL(R) Royalty for $6 Million... |
|
02 |
Aug 2016 |
IntelGenx to Report Second Quarter 2016 Financial Results on August 11, 2016... |
|
13 |
Jul 2016 |
IntelGenx to Initiate Phase 1 Trial of Montelukast... |
|
11 |
Jul 2016 |
IntelGenx Announces Notice of Appeal for Buprenorphine/Naloxone Sublingual Film Product for the Treatment of Opiate Addi... |
|
05 |
Jul 2016 |
IntelGenx and RedHill Biopharma Announce Signing of Definitive Agreement for Commercialization of RIZAPORT(TM) with Grup... |
|
12 |
May 2016 |
IntelGenx Reports Amendment of Stock Option Plan... |
|
10 |
May 2016 |
IntelGenx Reports First Quarter 2016 Financial Results... |
|
05 |
May 2016 |
IntelGenx to Report First Quarter 2016 Financial Results on May 10, 2016... |
|
29 |
Mar 2016 |
IntelGenx and RedHill Biopharma Announce RIZAPORT(TM) Commercialization Term Sheet With Grupo Juste for Spain and Additi... |
|
24 |
Mar 2016 |
IntelGenx Announces Development and Commercialization Term Sheet with a Global Pharmaceutical Company for Up to Three Pr... |
|
22 |
Mar 2016 |
IntelGenx Reports Record 2015 Financial Results... |
|
09 |
Mar 2016 |
IntelGenx to Host Conference Call and Webcast of Fourth Quarter and Full-Year 2015 Financial Results on Wednesday, March... |
|
02 |
Mar 2016 |
IntelGenx Appoints Dr. Dana Matzen as Vice President, Business Development... |
|
18 |
Feb 2016 |
IntelGenx Announces USPTO Has Granted Patent Protecting RIZAPORT(TM) Oral Film for Migraines... |
|
10 |
Feb 2016 |
IntelGenx Files Loxapine Oral Film Patent for Schizophrenia... |
|
04 |
Feb 2016 |
IntelGenx Announces Creation of a Scientific Advisory Board... |
|
28 |
Jan 2016 |
IntelGenx Appoints Mark Nawacki as Special Advisor... |
|
22 |
Jan 2016 |
IntelGenx Strengthens Senior Management Team... |